ArticleCureus2025
Trisulfated Heparin Disaccharide (TS-HDS) Antibody-Positive Small Fiber Neuropathy Involving Sweat Gland Nerve Fibers After the Second Moderna Vaccination: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 vaccinations (SC2V) may be complicated by small fiber neuropathy (SFN) in individual patients. Furthermore, SC2V-related SFN may be associated with antibodies against FGFR3 or recoverin, but no patient with SC2V-related SFN and elevated trisulfated heparin disaccharide (TS-HDS) antibodies has been described to date. The patient is a 74-year-old previously healthy woman who experienced temporary side effects after her second Moderna vaccination. One and two months later, more severe symptoms appeared, most of which persisted for the next four years. As sweat gland density was reduced and TS-HDS antibodies were elevated, she was diagnosed with TS-HDS-related SFN, which manifested as regional pain syndrome and autonomic dysfunction, but intravenous immunoglobulins (IVIGs) and naltrexone were ineffective. In addition to SFN, she was also diagnosed with mast cell activation syndrome (MCAS). This case demonstrates that SC2V with the Moderna vaccine can be complicated by long-lasting TS-HDS antibody-associated SFN and MCAS, which manifest as regional pain, autonomic dysfunction, cognitive impairment, anxiety, tinnitus, myalgia, fatigue, and easy fatigability. IVIGs may be ineffective, so immunosuppressants should be tried.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.